02391nam a2200481 i 4500 000711255 StDuBDS 20240202172917.0 20160518115749.0 m||||||||d|||||||| cr ||||||||||| 160408s2016 enka fo 000|0|eng|d NEZPRACOVANÝ IMPORT 9781473973367 (ebook) : No price (OCoLC)1017726104 StDuBDS eng StDuBDS rda pn HD49 658.4056 23 Elias, Jaan, author. Merck and Vioxx. (B), Merck settled claims for $4.85 billion / Jaan Elias & Constance E. Bagley. [London] : SAGE, 2016. 1 online resource : illustrations (black and white, and colour). text rdacontent still image rdacontent computer rdamedia online resource rdacarrier SAGE knowledge. Cases Originally Published in: Elias, J., Hutchins, S., Nagy, A., Bagley, C. E., & Rae, D. W. (2008). Merck and Vioxx (B): Merck Settled Claims for $4.85 Billion. 08-017. New Haven, CT: Yale School of Management, Yale University. Backing off their strategy to fight every single claim, Merck & Co. reached a settlement with a steering committee of plaintiffs' attorneys in November 2007. According to the agreement, the company would pay $4.85 billion to settle most claims arising from its Vioxx medication. Merck stressed that the settlement was not a class action. In addition, Merck did not admit to any fault in its sale of Vioxx. Lawsuits that had already gone to verdict would not be affected by the settlement. This study details the process of the legal settlement. Description based on online resource; title from home page (viewed on May 3, 2016). elektronické knihy fd186907 czenas electronic books eczenas Merck & Co. Crisis management Case studies. Actions and defenses Case studies. Bagley, Constance E., author. SAGE knowledge. Cases. SAGE knowledge https://sk.sagepub.com/cases/merck-and-vioxx-b-merck-settled-claims-for-billions-of-dollars Plný text SBC EB NEPOSILAT EB